PYC Therapeutics Ltd
ASX:PYC

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
ASX:PYC
Watchlist
Price: 1.23 AUD 0.41% Market Closed
Market Cap: 573.9m AUD
Have any thoughts about
PYC Therapeutics Ltd?
Write Note

P/FCFE
Price to FCFE

-14.9
Current
-20.5
Median
23.9
Industry
Higher than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-14.9
=
Market Cap
583.9m AUD
/
FCFE
-39.1m AUD
All Countries
Close
Market Cap P/FCFE
AU
PYC Therapeutics Ltd
ASX:PYC
583.9m AUD -14.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 088 857.4
US
Abbvie Inc
NYSE:ABBV
374.5B USD 17.1
US
Amgen Inc
NASDAQ:AMGN
168.4B USD 52.5
US
Gilead Sciences Inc
NASDAQ:GILD
140.9B USD 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.2B USD -136.6
US
Epizyme Inc
F:EPE
94.1B EUR -444.2
AU
CSL Ltd
ASX:CSL
120.3B AUD 53.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.1B USD 21.5
US
Seagen Inc
F:SGT
39.3B EUR -61.1
NL
argenx SE
XBRU:ARGX
32.3B EUR -105.6
 
AU
PYC Therapeutics Ltd
ASX:PYC
Average P/FCFE: 31.5
Negative Multiple: -14.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 088 857.4
US
Abbvie Inc
NYSE:ABBV
17.1
US
Amgen Inc
NASDAQ:AMGN
52.5
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -136.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -444.2
AU
CSL Ltd
ASX:CSL
53.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
21.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.6

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A